Episode 2110: Long Acting Injectables with Rochelle Perry PsychNP Cast

Meet Rochelle Perry PMHNP (rdperry05241@gmail.com) to learn about how she's worked with her son on his use of Long-Acting Injectables (LAIs) and how she uses them in her outpatient settings. There is a lot of strong clinical evidence that this patient care pathway helps and it's very easy, with low barriers to us providing it right in our office. Learn more about that... listen and enjoy.
References:
Greene, M., Yan, T., Chang, E., Hartry, A., Touya, M., and Broder, M. S. (2018). Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. Journal of Medical Economics, 21(2), 127–134. https://doi.org/10.1080/13696998.2017.1379412 (https://doi.org/10.1080/13696998.2017.1379412)
Kishimoto, T., Hagi, K., Nitta, M., Leucht, S., Olfson, M., Kane, J. M., and Correll, C. U. (2018). Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies. Schizophrenia Bulletin, 44(3), 603–619. https://doi.org/10.1093/schbul/sbx090 (https://doi.org/10.1093/schbul/sbx090)
Oliver, D., Davies, C., Crossland, G., Lim, S., Gifford, G., McGuire, P., and Fusar-Poli, P. (2018). Can We Reduce the Duration of Untreated Psychosis? A Systematic Review and Meta-Analysis of Controlled Interventional Studies. Schizophrenia Bulletin, 44(6), 1362–1372. https://doi.org/10.1093/schbul/sbx166
Subotnik, K., Casaus, L., Ventura, J., Luo, J., Hellemann, G., Gretchen-Doorly, D., Marder, S., and Nuechterlein, K. (2015). Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia : A Randomized Clinical Trial. JAMA Psychiatry (Chicago, Ill.), 72(8), 822–829. https://doi.org/10.1001/jamapsychiatry.2015.0270
Titus-Lay, E. N., Ansara, E. D., Isaacs, A. N., and Ott, C. A. (2018). Evaluation of adherence and persistence with oral versus long-acting injectable antipsychotics in patients with early psychosis. The Mental Health Clinician, 8(2), 56–62. https://doi.org/10.9740/mhc.2018.03.056 (https://doi.org/10.9740/mhc.2018.03.056)
Velligan, D. I., Maples, N. J., Pokorny, J. J., and Wright, C. (2020). Assessment of adherence to oral antipsychotic medications: What has changed over the past decade?. Schizophrenia Research, 215, 17–24. https://doi.org/10.1016/j.schres.2019.11.022 (https://doi.org/10.1016/j.schres.2019.11.022)
Weiden, P. J., Claxton, A., Kunovac, J., Walling, D. P., Du, Y., Yao, B., Yagoda, S., Bidollari, I., Keane, E., and Cash, E. (2020). Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study. The Journal of Clinical Psychiatry, 81(3), 19m13207. https://doi.org/10.4088/JCP.19m13207
Contact PsychNP CastWant to be a guest? Fill this form out: https://forms.gle/tTQ8nChFaV4tKEj38 (https://forms.gle/tTQ8nChFaV4tKEj38)
Email us Email: PsychNPcast@gmail.com